Phase 3, double blinded, placebo controlled study of the effects of 12 weeks DPP-IV inhibitor treatment on secretion and action of the incretin hormones in patients with type 2 diabetes

Trial Profile

Phase 3, double blinded, placebo controlled study of the effects of 12 weeks DPP-IV inhibitor treatment on secretion and action of the incretin hormones in patients with type 2 diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Aug 2014

At a glance

  • Drugs Sitagliptin (Primary) ; CD26 antigen inhibitors
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Nov 2012 Investigational drug identified as Sitagliptin as reported by European Clinical Trials Database.
    • 05 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top